List of Excipients in Branded Drug MYOBLOC

« Back to Dashboard

MYOBLOC Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 29, 2026

MYOBLOC is a liquid, refrigerated botulinum toxin type B product containing rimabotulinumtoxinB. Its formulation uses human serum albumin, sodium chloride, and sodium succinate. The principal commercial opportunity is not a conventional generic excipient substitution. It is a differentiated formulation platform focused on stability, reduced handling, animal-origin-free composition, delivery-device compatibility, and manufacturing process control.

MYOBLOC is marketed in the United States by US WorldMeds, a subsidiary of Supernus Pharmaceuticals. The product is approved for cervical dystonia and chronic sialorrhea. Its liquid, ready-to-use presentation avoids reconstitution, but refrigerated storage, biologic potency testing, immunogenicity, and limited clinical adoption constrain market entry by alternative products.[1]

What is the MYOBLOC formulation and which excipients does it contain?

MYOBLOC is a sterile injectable solution of rimabotulinumtoxinB supplied in single-use vials. The labeled presentations are 2,500 units per 0.5 mL, 5,000 units per 1 mL, and 10,000 units per 2 mL.[1]

The labeled inactive ingredients are:

Component	Formulation role	Commercial relevance
Human serum albumin	Protein stabilizer and surface-protection agent	Creates sourcing, viral-safety, and animal-origin concerns; may limit positioning against newer recombinant or albumin-free products
Sodium chloride	Tonicity adjustment	Low-cost, established parenteral excipient
Sodium succinate	Buffering and pH control	Supports solution stability and may influence toxin activity during storage
Water for injection	Vehicle	Standard sterile injectable component

The product is supplied as a liquid rather than a lyophilized powder. MYOBLOC must be stored at 2°C to 8°C and protected from light. The labeled product is not frozen and is not shaken.[1]

The formulation’s commercial logic is straightforward: a liquid presentation eliminates reconstitution steps and reduces preparation time in a physician office. Its limitations are equally important. The product remains dependent on refrigerated distribution, careful handling, a validated potency assay, and a biologically active neurotoxin that can lose activity through adsorption, aggregation, or interface exposure.

Why is human serum albumin important in MYOBLOC?

Human serum albumin can stabilize proteins by reducing adsorption to glass, polymeric surfaces, and other interfaces. It can also reduce concentration-dependent instability in dilute protein solutions.

The drawbacks are strategic:

1. Albumin is a human-derived raw material requiring controlled sourcing and viral-safety documentation.
2. Albumin can complicate “animal-origin-free” or “human-component-free” product positioning.
3. Albumin-based formulations may be less attractive for next-generation products targeting simplified global manufacturing.
4. Albumin substitution requires evidence that the replacement maintains potency, purity, aggregation control, sterility, and immunogenicity performance.

An albumin-free MYOBLOC formulation could support a differentiated product or licensing program, but the technical hurdle is high. The replacement must provide equivalent interfacial protection without increasing aggregates or altering the toxin’s biological activity.

What excipient strategy is most attractive for MYOBLOC?

The highest-value strategy is a platform approach rather than a single-excipient substitution. Candidate development should target four attributes: stability, manufacturability, patient and physician convenience, and regulatory differentiation.

Albumin-free stabilization

Potential stabilizer classes include recombinant human albumin, polysorbates, poloxamers, amino acids, sugars, polyols, and selected nonionic surfactants. Each category creates a different risk profile.

Strategy	Potential benefit	Principal risk
Recombinant human albumin	Retains albumin-like stabilization with lower donor-material dependence	Cost, supply qualification, comparability burden
Polysorbate or poloxamer system	Reduces surface adsorption and interface stress	Oxidation, peroxide impurities, particle formation
Trehalose or sucrose	May stabilize protein structure during stress and freezing	Osmolality, viscosity, degradation pathways
Amino-acid formulation	May improve solubility and reduce aggregation	Limited predictability for a complex neurotoxin
Lyophilized presentation	Improved storage flexibility and potentially longer shelf life	Reconstitution burden, cake quality, recovery, potency loss
Low-temperature liquid formulation	Preserves current user convenience	Continued cold-chain dependence

No candidate should be treated as interchangeable with the existing MYOBLOC excipient system. Botulinum neurotoxins are large, sensitive proteins whose potency depends on structural integrity and the performance of the assay used to release each lot.

Surfactant strategy

A surfactant may reduce adsorption during filling, storage, and administration. The main development questions are surfactant concentration, peroxide burden, container interaction, visible and subvisible particles, and long-term potency.

For MYOBLOC, the strongest commercial opportunity would be a low-surfactant or surfactant-free composition that achieves equivalent stability while reducing oxidation and particulate risk. A broad patent claim covering any stabilizing surfactant would face prior-art pressure. A more defensible claim could combine a specific excipient concentration range with a defined storage condition and a measured potency or aggregation result.

Buffer and pH strategy

Sodium succinate is part of the existing formulation. A reformulation program could evaluate citrate, histidine, phosphate, acetate, or alternative succinate concentrations. The patent value would depend on demonstrated performance rather than the buffer name alone.

A commercially useful buffer patent would link composition to an objective result, such as:

• retained potency after extended refrigerated storage;
• lower aggregate formation;
• reduced adsorption to the primary container;
• improved recovery after simulated administration;
• stability in a prefilled syringe or injection device.

What patents protect MYOBLOC and its formulation?

MYOBLOC is a biologic licensed under FDA BLA 125041 rather than a conventional small-molecule product listed through an FDA New Drug Application. The principal protection historically associated with botulinum toxin products has included composition, purification, pharmaceutical formulation, manufacturing, potency testing, and therapeutic-use claims.

The Orange Book is not the primary patent reference for MYOBLOC. Approved biologics are generally tracked through the Purple Book and FDA biologics records, while patent rights must be assessed through USPTO records, assignment data, prosecution histories, litigation dockets, and relevant foreign registers.[2,3]

A complete MYOBLOC freedom-to-operate review should separate four patent groups:

Patent group	Typical claims	Risk to a competing product
Toxin composition patents	Botulinum toxin type B, complexes, fragments, or purified forms	Potentially high if claims remain enforceable in the target market
Formulation patents	Stabilizers, buffers, albumin systems, pH, concentration, or liquid stability	Direct risk to albumin-free or extended-stability products
Manufacturing patents	Fermentation, purification, activation, filtration, filling, and potency assays	May block commercial manufacture even where formulation claims are avoided
Method-of-use patents	Cervical dystonia, sialorrhea, dosing, injection patterns, or patient subgroups	Relevant to label expansion and commercial promotion

A formulation patent is strongest when it claims a narrow composition supported by comparative data. Generic claims to a botulinum toxin plus a conventional buffer or protein stabilizer are more exposed to obviousness and written-description challenges.

When does MYOBLOC lose exclusivity?

MYOBLOC received its initial U.S. approval in 2000. Because it predates the March 23, 2010 effective date of the Biologics Price Competition and Innovation Act, the statutory 12-year reference-product exclusivity period does not operate as a new exclusivity clock for MYOBLOC in the same manner as it does for a post-2010 reference biologic.[4]

Commercial exclusivity therefore depends primarily on:

• enforceable patents;
• manufacturing know-how;
• regulatory exclusivity associated with any later supplements;
• clinical data needed for a biosimilar or follow-on product;
• physician adoption and reimbursement;
• supply reliability.

There is no conventional small-molecule Hatch-Waxman expiration date that independently determines generic entry for MYOBLOC.

What is the FDA and Orange Book status of MYOBLOC?

MYOBLOC is an FDA-approved biologic under BLA 125041. It is not a conventional small-molecule drug with an ANDA pathway and does not have the same Orange Book patent-listing structure as an NDA product.[1,2]

A competing developer would likely assess one of two routes:

1. A biosimilar or interchangeable biologic pathway under the BPCIA, if the product and reference-product framework are available.
2. A separate BLA for a distinct botulinum toxin type B product, supported by its own manufacturing, analytical, clinical, and safety package.

The biosimilar pathway may reduce clinical development requirements, but it does not eliminate the need to demonstrate highly similar structure, function, potency, purity, and immunogenicity. Botulinum toxin products also raise product-specific questions about biological activity, serotype-specific pharmacology, assay comparability, and neutralizing antibodies.

As of the FDA Purple Book records available through mid-2024, no FDA-approved biosimilar to MYOBLOC had been listed.[2]

Are Paragraph IV challenges relevant to MYOBLOC?

Traditional Paragraph IV litigation is generally not the central challenge mechanism for MYOBLOC because Paragraph IV applies to patents listed for approved small-molecule drugs under the Hatch-Waxman framework.

A competing biologic developer would instead face:

• BPCIA patent information exchange procedures;
• patent litigation concerning manufacturing, formulation, or use claims;
• declaratory-judgment or infringement actions;
• regulatory disputes over biosimilarity or interchangeability;
• trade-secret and know-how risks.

Any proposed follow-on product should assume that process patents and formulation patents may be more commercially important than the absence of Orange Book listings.

What formulation patents could create commercial opportunities?

The most attractive patentable opportunities are narrow, data-supported formulations that solve a specific commercial problem.

Refrigerated liquid formulation

An improved liquid formulation could target a longer shelf life at 2°C to 8°C, reduced sensitivity to agitation, or improved stability after removal from controlled refrigeration. Claims would need to define the excipient system and demonstrate a measurable advantage over the reference formulation.

Room-temperature or excursion-tolerant formulation

A product that tolerates defined periods outside refrigeration could reduce distributor write-offs, improve clinic handling, and expand use in markets with weaker cold-chain infrastructure. The technical challenge is maintaining potency and controlling aggregation during temperature excursions.

Prefilled syringe or cartridge

A device-compatible MYOBLOC presentation could reduce vial waste and dosing errors. The patent estate could combine:

• low-binding container materials;
• extractables and leachables controls;
• toxin-compatible lubricants;
• dose-volume specifications;
• storage conditions;
• delivery-device operating parameters.

Container-closure patents may provide a more defensible barrier than broad excipient claims if the device materially improves administration.

Lyophilized or dual-chamber presentation

A lyophilized product could improve transport flexibility, but it would impose reconstitution steps that reduce one of MYOBLOC’s current convenience advantages. A dual-chamber device could offset that burden, but device complexity would increase development cost and regulatory risk.

Animal-origin-free formulation

An animal-origin-free or human-component-free product could appeal to institutional buyers and international markets. The key commercial advantage would be procurement and manufacturing simplification, not merely a different ingredient list.

Which companies are challenging MYOBLOC?

No company had an FDA-approved MYOBLOC biosimilar as of mid-2024. The competitive field is therefore defined by other botulinum toxin products rather than a direct generic substitute.

Product	Active toxin	Primary sponsor or manufacturer	Main competitive overlap
MYOBLOC	Botulinum toxin type B	US WorldMeds/Supernus	Cervical dystonia and sialorrhea
BOTOX	Botulinum toxin type A	AbbVie/Allergan	Broad therapeutic and aesthetic use
Dysport	Botulinum toxin type A	Ipsen	Therapeutic and aesthetic use
Xeomin	Botulinum toxin type A	Merz	Therapeutic and aesthetic use
DAXXIFY	Botulinum toxin type A	Revance Therapeutics	Long-duration positioning and peptide excipient technology

These products are not automatically substitutable. Serotype, potency units, dosing, onset, duration, immunogenicity, approved indications, and physician familiarity differ across products. The competitive threat to MYOBLOC is therefore more likely to come from therapeutic substitution by botulinum toxin type A products than from an immediate biosimilar launch.

How strong is the MYOBLOC patent estate?

The commercial strength of the MYOBLOC estate is likely greater in manufacturing know-how and biological-product execution than in a broad, easily identified formulation monopoly.

A practical strength assessment should score:

Factor	Assessment
Regulatory barrier	High because botulinum toxin products require specialized potency, purity, and safety packages
Formulation barrier	Moderate; liquid protein formulations are technically difficult but use established excipient concepts
Manufacturing barrier	High; fermentation, purification, activation, filling, and potency control require specialized capability
Orange Book barrier	Limited because MYOBLOC is not protected through the standard Orange Book pathway
Biosimilar barrier	High analytical and regulatory burden, with no established MYOBLOC biosimilar precedent
Formulation patent durability	Dependent on claim scope, prosecution history, terminal disclaimers, and expiration status
Trade-secret value	Potentially high for purification, stabilization, and potency-assay methods

Patent expiration must be determined patent by patent. The 20-year term generally runs from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any available patent-term extension.[5] Approval in 2000 does not establish the expiration date of every patent associated with the product.

What licensing deals could support a MYOBLOC excipient program?

Licensing targets would fall into four categories:

1. Recombinant albumin or albumin alternatives.
2. Protein-stabilizing excipient systems with parenteral precedent.
3. Low-binding syringe, cartridge, and vial technologies.
4. Manufacturing and analytical platforms for botulinum toxin products.

A licensee should seek rights covering both composition and use in botulinum toxin formulations. A general excipient license may not provide freedom to operate if the relevant patent claims the combination of the excipient with a neurotoxin, a defined pH range, a particular container, or a storage condition.

The preferred deal structure would include field-of-use exclusivity for botulinum toxin type B, access to stability data, analytical methods, supply rights, and rights to improvements. Royalty economics should reflect whether the technology improves shelf life, removes human albumin, enables room-temperature excursions, or reduces manufacturing loss.

What revenue exposure does MYOBLOC create for reformulation or competition?

MYOBLOC addresses a narrower commercial market than the leading botulinum toxin type A products. Its revenue exposure is concentrated in:

• cervical dystonia;
• chronic sialorrhea;
• physician-office administration;
• specialist prescribers;
• hospital and clinic procurement;
• patients who are established on botulinum toxin type B.

A successful alternative formulation would not need to displace every MYOBLOC use. It could capture value through lower manufacturing cost, improved gross margin, reduced cold-chain loss, longer shelf life, or a new presentation that increases clinic utilization.

The strongest commercial scenario is a differentiated follow-on product with:

• equivalent or improved biological activity;
• reduced dependence on human albumin;
• simplified storage;
• a prefilled or low-waste delivery format;
• a regulatory strategy that supports a distinct BLA or biosimilar development program.

Key Takeaways

• MYOBLOC is a refrigerated liquid rimabotulinumtoxinB product containing human serum albumin, sodium chloride, and sodium succinate.
• Its leading excipient opportunity is an albumin-free or recombinant-albumin formulation with equivalent potency and improved supply-chain positioning.
• A room-temperature excursion-tolerant product could reduce distribution and clinic-handling costs.
• MYOBLOC is regulated under a biologics framework, not as a conventional Orange Book small-molecule product.
• Paragraph IV litigation is generally not the relevant pathway; BPCIA patent procedures and BLA litigation are more important.
• No FDA-approved MYOBLOC biosimilar was listed through mid-2024.
• Manufacturing know-how, potency assays, container compatibility, and formulation data may provide stronger barriers than broad excipient claims.
• The main competitive threat is therapeutic substitution by botulinum toxin type A products.
• Patent expiration must be evaluated individually from issued patent records, not inferred from the 2000 approval date.

FAQs

Can MYOBLOC be reformulated without new clinical trials?

A material formulation change may require new clinical or bridging data. The need depends on the change, analytical comparability, potency results, stability profile, immunogenicity risk, and FDA’s regulatory classification of the supplement or new application.

Is human serum albumin required for botulinum toxin type B stability?

No universal requirement applies. Albumin is used as a stabilizer in the MYOBLOC formulation, but an alternative system could be developed if it demonstrates equivalent or superior stability, potency, purity, and safety.

Could a biosimilar use different excipients from MYOBLOC?

Yes. A biosimilar does not have to use identical inactive ingredients in every case. The sponsor must demonstrate that the formulation differences do not affect similarity, safety, purity, potency, or immunogenicity.

Would a prefilled MYOBLOC syringe create a new patent opportunity?

Yes. Patentable subject matter could include the formulation-device combination, low-binding materials, dose-volume configuration, storage conditions, and delivery performance. Device claims would need to avoid blocking patents held by the syringe or cartridge manufacturer.

Is a MYOBLOC generic possible under an ANDA?

An ANDA is generally not the standard route for a biologic such as MYOBLOC. A competing developer would normally evaluate a biosimilar pathway or pursue a separate biologics license application, depending on the product’s regulatory classification and development strategy.

References

1. U.S. Food and Drug Administration. (2023). MYOBLOC (rimabotulinumtoxinB) injection, prescribing information. US WorldMeds, LLC.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugsatfda

4. Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119 (2010).

5. United States Patent and Trademark Office. (2024). Patent term calculator and patent term adjustment information. https://www.uspto.gov/patents/laws/patent-term-calculator